Bazal'naya insulinoterapiya: opyt klinicheskoy praktiki


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The article presents the review of data on the effectiveness and safety of insulin glargine. The several studies have shown that the administration of insulin glargine allows to achieve and maintain target blood glucose control without body weight gain, has no effect on cardiovascular outcomes, does not cause an increased risk of developing any form of cancer. The authors conclude that the basal insulin can be appointed in combination with oral antidiabetic drugs for the initiation of insulin therapy in patients with type 2 diabetes mellitus.

Толық мәтін

Рұқсат жабық

Авторлар туралы

N. Chernikova

Email: nachendoc@yandex.ru

A. Ametov

M. Antsiferov

Әдебиет тізімі

  1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compered with conventional treatment and risk of complications in patients with typel diabetes (UKPDS) Lancet 1998;352:837-53.
  2. Goldberg RB, Holman R, Drucker DJ. N. Clinical decisions. Management of type 2 diabetes. Engl J Med 2008;358:293-97.
  3. Davidson MB. Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care 2005;28:222-24.
  4. Polonsky WH, Fisher L, Gusman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-45.
  5. Nakar S, Yitzhaki G, Rosenberg R, et al. Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications 2007; 21:220-26.
  6. Анциферов М.Б. Гликемический контроль у пациентов с сахарным диабетом типа 2 во время инициации инсулинотерапии в реальной клинической практике Российской Федерации: результаты исследования CREDIT // Фарматека 2009. № 17.
  7. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367(4): 319-28.
  8. Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-88.
  9. Selam JL, Kochen C, Weng W, et al. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008;24:11 -20.
  10. Owens DR, Bolli GB. Beyond the era of NPH insulin: long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 2008; 10:333-49.
  11. Rosenstock J, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009; 52:639-43.
  12. Home PD, et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010;12:772-79.
  13. Schreiber S, Russman A. Improved metabolic control with a favorable weight profile in patients with type 2 diabetes treated with insulin glargin in clinical practice. Diabetes 2002; 51 (Suppl. 2):114:A464-P.
  14. Mannucci E., Manami M., Marchianni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes. Metab 2009;11:53-9.
  15. Davies M, Lavalle-Gonzalez F, Storms F, Gomis R. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab 2008; 10(5):387-99
  16. Monnier L. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002;25:737-41.
  17. Monnier L, Colette C. Contribution of postprandial glucose to chronic hyperglycaemia: from the «glucose triad» to the trilogy of «sevens». Diabetes Metab 2006;32:7-13.
  18. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011;13:703-10.
  19. Riddle M, Home PD, Marre M, Niemoeller E, Ping L, Rosenstock J. Efficacy and safety of once-daily lixisenatide in type 2 diabetes insufficiently controlled with basal insulin ± metformin: GetGoal-L study. ADA 2012. Poster abstract 983-P.
  20. Seino Y, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012;14(10): 910-17.
  21. Rosenstock J, Forst T, Aronson R, et al. Efficacy and safety of once-daily lixisenatide added on to titrated glargine plus oral agents in type 2 diabetes: GetGoal-Duo 1 study. Diabetes 2012; 61(suppl. 1):A17.
  22. Глинкина И.В., Романцова Т.И. Результаты наблюдательной программы по применению инсулина гларгин (Лантус®) в комбинации с пероральными сахароснижающими препаратами для лечения сахарного диабета 2 типа в повседневной клинической практике // Фарматека 2011. №3. C. 65-68

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2013

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>